Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer

Translational Lung Cancer Research

Volumn 3, Issue 6, 2014, Pages 379-381

  Rothschild, Sacha I ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CRIZOTINIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG RESPONSE; EDITORIAL; HUMAN; HYPOPHOSPHATEMIA; MAXIMUM TOLERATED DOSE; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; VOMITING;

EID: 84957948149     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.11.09     Document Type: Editorial

References (10)

1. Scagliotti G, Stahel RA, Rosell R, et al. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer 2012;48:961-73.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
3. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lungcancer. Clin Cancer Res 2008;14:4275-83.
4. Rothschild SI, Gautschi O. Crizotinib in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2013;14:473-80.
5. Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32:abstr 8002.
6. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013;5:209ra153.
7. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82.
8. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73.
9. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALKrearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-1197.
10. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.